Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26964977 | 1.00 | BACE1 (0.35) | BACE1HPGDSMN1; SMN2CCNE1CDK2 | |
| SCHEMBL26964564 | 0.82 | SMN1; SMN2 (0.39) | BACE1HPGDSMN1; SMN2CCNE1CDK2 | |
| SCHEMBL30645653 | 0.82 | SMN1; SMN2 (0.39) | BACE1HPGDSMN1; SMN2CCNE1CDK2 | |
| SCHEMBL26964795 | 0.78 | SMN1; SMN2 (0.41) | BACE1HPGDSMN1; SMN2CCNE1CDK2 | |
| SCHEMBL26964688 | 0.78 | SMYD2 (0.33) | HPGDSMN1; SMN2 | |
| SCHEMBL29987604 | 0.78 | CCNE1 (0.39) | BACE1HPGDSMN1; SMN2CCNE1CDK2 | |
| SCHEMBL14461324 | 0.77 | BACE1 (0.43) | BACE1SMN1; SMN2 | |
| SCHEMBL30714138 | 0.75 | HPGD (0.36) | BACE1HPGDSMN1; SMN2 | |
| SCHEMBL30714285 | 0.75 | HPGD (0.36) | BACE1HPGDSMN1; SMN2 | |
| SCHEMBL25106731 | 0.75 | BACE1 (0.39) | BACE1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-4291176-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | CDK3, CDK8, CDK6 | BACE1 1699/4885HPGD 1778/4885SMN1; SMN2 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.